Early Phase 1 N=27 Age Comparisons of Exercising Muscle O2 Supply in Healthy Adults: Effects of Esmolol Infusion
Aging
Primary: Tissue Saturation Index (TSI) - Active Leg Muscle — -5.1; -3.1; -8.7; -6.3 % Total Labile Signal
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=35 Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers
Locally Advanced Malignant Solid Neoplasm
Primary: Pathological Complete Response (pCR). — 67 Percentage
N/A N=2,105 The United States Healthy Living Study
Colo-rectal Cancer
Primary: Intention to Talk to Doctor About Colorectal Cancer Screening — 4.14; 4.0; 3.59; 3.48 units on a scale
N/A N=94 Femtosecond Laser Assisted Keratotomies for the Management of Corneal Astigmatism
Astigmatism · Cataract
Primary: Keratometric Correction Index — 0.51 index
Phase 1 N=32 Telehealth Virtual Reality Gaming on Cardiometabolic Health Among Youth With Cerebral Palsy
Cerebral Palsy
Primary: Changes in C-reactive Protein (hsCRP) — 2.32; 2.66 mg/L
N/A N=548 North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
Epilepsy; Seizure · Neuromuscular Diseases · Brain Malformation
Primary: Initial Patient Pediatric Quality of Life (Peds QL) Score — 64.37; 65.83; 60.04; 63.39 score on a scale
Phase 3 N=115 Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)
Suspected or Documented Gram-negative Bacterial Infection
Primary: Percentage of Participants With One or More Adverse Event (AE) — 60.0; 50.0; 64.5; 36.4 Percentage of Participants
Phase 2 N=40 Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies
Bladder Cancer · Gastric Cancer · Non Small Cell Lung Cancer
Primary: To Evaluate the Safety of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumors. — 6; 6; 5; 20 participants
N/A N=22 QT Changes as Detected From LINQ ECG During Antiarrhythmic Loading (LINQ QT)
Atrial Arrhythmia · QT Interval, Variation in · Arrhythmias, Cardiac
Primary: QT Intervals During Antiarrhythmic Loading Hospitalization — 21.8 milliseconds
N/A N=18,693 Paediatric Rapid Sepsis Trigger (PRST) Tool
Sepsis · Infection
Primary: Time to Administration of an Appropriate Antimicrobial — 115; 123; 239; 261 minutes
N/A N=40 Pilot RCT of a Video-based Intervention for Suicide Prevention
Suicidal Ideation · Suicidal Behaviors · Suicide
Primary: Client Satisfaction Questionnaire (CSQ) — 25.6; 24.6 score on scale
Phase 2 N=15 Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma
Mantle Cell Lymphoma
Primary: Progression Free Survival Rate (PFS) at 2 Years Post-Blood or Marrow Transplant (BMT) — 73.5 percentage of participants
Early Phase 1 N=10 Study of Modified Atkins Diet in Kabuki Syndrome
Kabuki Syndrome
Primary: Benton Judgement of Line Orientation — 8.6; 11.6 score on a scale
Phase 2 N=48 Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain
Metastatic Melanoma · Brain Metastases
Primary: Intracranial Objective Response (iORR) by Modified RECIST 1.1 Before Local Radiotherapy Treatment in Full Dataset — 34; 13; 1; 20 Participants
N/A N=188 STEM-Parkinson's Disease
Parkinson Disease · Parkinson's Disease and Parkinsonism
Primary: Change in The International Parkinson and Movement Disorder Society Non-Motor Rating Scale (MDS-NMS) Total Score — -21.2; -18.3 score on a scale